Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
KB Home
KBH
4
Vale SA
VALE
5
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 38.930
- -0.740-1.87%
Trading Mar 26 13:51 ET
2.46BMarket Cap-20.60P/E (TTM)
40.340High38.800Low298.15KVolume39.600Open39.670Pre Close11.69MTurnover1.06%Turnover RatioLossP/E (Static)63.28MShares58.26052wk High5.51P/B1.10BFloat Cap36.52052wk Low--Dividend TTM28.21MShs Float64.980Historical High--Div YieldTTM3.88%Amplitude4.250Historical Low39.205Avg Price1Lot Size
MoonLake Immunotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 164.38%143.09M | 229.90%49.58M | 232.23%43.11M | 131.90%30.58M | 53.27%19.82M | -16.81%54.12M | -9.99%15.03M | -12.14%12.98M | -25.30%13.19M | -18.89%12.93M |
| Selling and administrative expenses | 35.83%30.32M | 33.03%9.22M | 36.81%7.38M | 54.31%6.92M | 23.38%6.81M | -3.00%22.32M | 30.11%6.93M | -6.17%5.39M | -28.31%4.48M | 0.53%5.52M |
| -General and administrative expense | 35.83%30.32M | 33.03%9.22M | 36.81%7.38M | 54.31%6.92M | 23.38%6.81M | -3.00%22.32M | 30.11%6.93M | -6.17%5.39M | -28.31%4.48M | 0.53%5.52M |
| Research and development costs | 254.61%112.77M | 398.40%40.36M | 371.13%35.74M | 171.86%23.66M | 75.51%13.01M | -24.37%31.8M | -28.77%8.1M | -15.95%7.59M | -23.65%8.7M | -29.08%7.42M |
| Operating profit | -164.38%-143.09M | -229.90%-49.58M | -232.23%-43.11M | -131.90%-30.58M | -53.27%-19.82M | 16.81%-54.12M | 9.99%-15.03M | 12.14%-12.98M | 25.30%-13.19M | 18.89%-12.93M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | 118.27%22.13M | -55.11%3.23M | 411.41%7.09M | 599.95%5.9M | 717.48%5.92M | 1,613.34%10.14M | 2,900.28%7.19M | 3,587.69%1.39M | 243.76%842.65K | 941.05%723.59K |
| Gain on sale of security | ---- | ---- | 95.20%-26.75K | -136.10%-39.29K | ---- | ---- | ---- | ---557.14K | --108.84K | ---- |
| Other non- operating income (expenses) | 118.27%22.13M | -55.13%3.1M | 266.17%7.12M | 709.13%5.94M | 717.48%5.92M | 1,613.34%10.14M | 2,784.83%6.91M | 5,069.73%1.94M | 199.35%733.81K | 941.05%723.59K |
| Income before tax | -175.01%-120.96M | -491.02%-46.35M | -210.79%-36.02M | -99.95%-24.68M | -13.90%-13.91M | 31.77%-43.98M | 52.34%-7.84M | 21.33%-11.59M | 29.09%-12.34M | 23.09%-12.21M |
| Income tax | 198.98%282.2K | -7.15%41.14K | 218.45%92.11K | 675.46%78.7K | 538.07%70.25K | 159.55%94.39K | 302.36%44.31K | 230.93%28.92K | 9.34%10.15K | 50.16%11.01K |
| Net income | -175.06%-121.24M | -488.23%-46.4M | -210.81%-36.11M | -100.42%-24.76M | -14.38%-13.98M | 31.67%-44.08M | 52.10%-7.89M | 21.18%-11.62M | 29.07%-12.35M | 23.05%-12.22M |
| Net income continuous Operations | -175.06%-121.24M | -488.23%-46.4M | -210.81%-36.11M | -100.42%-24.76M | -14.38%-13.98M | 31.67%-44.08M | 52.10%-7.89M | 21.18%-11.62M | 29.07%-12.35M | 23.05%-12.22M |
| Minority interest income | 71.40%-2.31M | -75.70%-791.19K | 66.99%-724.09K | 77.79%-491.74K | 90.61%-301.87K | 44.46%-8.07M | -170.37%-450.31K | 52.64%-2.19M | 58.19%-2.21M | -3.21M |
| Net income attributable to the parent company | -230.31%-118.94M | -513.20%-45.6M | -275.45%-35.39M | -139.34%-24.27M | -51.85%-13.67M | 27.95%-36.01M | 56.53%-7.44M | 6.77%-9.43M | 16.35%-10.14M | 43.29%-9M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -230.31%-118.94M | -513.20%-45.6M | -275.45%-35.39M | -139.34%-24.27M | -51.85%-13.67M | 27.95%-36.01M | 56.53%-7.44M | 6.77%-9.43M | 16.35%-10.14M | 43.29%-9M |
| Basic earnings per share | -158.90%-1.89 | -620.00%-0.72 | -211.11%-0.56 | -69.57%-0.39 | 4.35%-0.22 | 57.06%-0.73 | 67.74%-0.1 | 33.33%-0.18 | 32.35%-0.23 | 46.52%-0.23 |
| Diluted earnings per share | -158.90%-1.89 | -620.00%-0.72 | -211.11%-0.56 | -69.57%-0.39 | 4.35%-0.22 | 57.06%-0.73 | 67.74%-0.1 | 33.33%-0.18 | 32.35%-0.23 | 46.52%-0.23 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025